DynamX Bioadaptor RCT Two-Year Outcomes: Significant Advantages vs DES
-
1m 46sPart 2 | Session 1 Summary of Outcomes of Bioadaptor RCT Two-Year
-
2m 40sPart 2 | Session 2 Summary of Outcomes of Bioadaptor RCT Two-Year (Japanese)
Recorded at EuroPCR 2024 in Paris, these interviews provide insight into the Bioadaptor RCT trial.
Learning Objectives
- Understand the clinical design and goal of the Bioadaptor RCT study
- Review the clinical endpoints and results of the study at two-year follow-up
- Discover the clinical practice implications of the study
Target Audience
- Interventional Cardiologists
- PCI Operators
More from this programme
Part 1
Perspective on DynamX Bioadaptor RCT Two-Year Outcomes
In this insightful interview, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, SA) is delving into the two-year findings of the Bioadaptor RCT trial, recently presented at the EuroPCR Conference in May 2024.1 This interview will provide a comprehensive review of the trial and findings, highlighting the potential implication for the current clinical practice.
Dr Alasnag will examine the design, methodology and outcomes, offering an in-depth interpretation of the results. Additionally, Dr Alasnag will explore the clinical implications of these findings to discuss the next steps and potential impact on the future of PCI in light of the trial findings.
References:
1. Bioadaptor RCT 2 year outcomes. S. Saito. EuroPCR 2024.
Part 2
Summary of Outcomes of Bioadaptor RCT Two-Year
Dr Saito, the primary investigator of Bioadaptor RCT, shares a quick summary of the two-year outcomes presented at EuroPCR 2024. EuroPCR 2024 recognised the two-year Bioadaptor RCT results as one of the top three trial updates. Dr Saito highlights how the novel design and mechanism of action of DynamX Bioadaptor restores haemodynamic modulation to the artery, delivers sustained significant clinical benefit, establishing a new therapy and potentially a new standard of treatment for patients with CAD.1
References:
1. Bioadaptor RCT 2 year outcomes. S. Saito. EuroPCR 2024.
Faculty Biographies
Mirvat Alasnag
Director of Catheterization Laboratory
Dr. Mirvat Alasnag is a consultant interventional cardiologist based in Jeddah, Saudi Arabia. She is Director of the Catheterization Laboratory at King Fahad Armed Forces Hospital, where she has played a central role in the development of contemporary interventional cardiology services. Dr. Alasnag is recognised as the first female interventional cardiologist in the Gulf region and has been a prominent advocate for women in cardiology, representing female physicians on multiple national and international committees.
Academic History
Dr. Alasnag completed her training in Clinical Cardiology at Loma Linda University Medical Center in Loma Linda, California. She subsequently undertook advanced training in Interventional Cardiology at Harper University Hospital, Detroit Medical Center, in Detroit, Michigan. Her training combined high-volume clinical practice with exposure to complex coronary interventions, forming the foundation for her subsequent leadership…
Comments